GB Pant Institute of Post Graduate Medical Education & Research

New Delhi 110002

3 studies enrolling now · 16 studies all time

What they study most

Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Disease With Mention of Arteriosclerosis, Cardiovascular Diseases, Cardiovascular Risk Factor, Cardiovascular Stroke, Chronic Kidney Disease (CKD), Chronic Migraine, Colitis, Ulcerative, Elevated Cholesterol, Elevated Lp(a), Episodic Migraine, Familial Hypercholesterolemia

Studies at this site

• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension — Running, not enrolling
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) — Running, not enrolling
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 — Running, not enrolling
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 — Running, not enrolling
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine — Running, not enrolling
• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine — Running, not enrolling
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction — Enrolling by invitation
• Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction — Status unconfirmed
• Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH — Completed